FindTrial
Sign In

A phase II GISL study of R-HyperCVAD in the treatment of patients with Mantle cell Lymphoma

A phase II GISL study of R-HyperCVAD in the treatment of patients with Mantle cell Lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-001500-39-IT
Enrollment
Unknown
Registered
2007-08-06
Start date
2005-09-06
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

treatment of patients with Mantle cell Lymphoma with tha combination R-HyperCVAD MedDRA version: 9.1 Level: LLT Classification code 10061275 Term: Mantle cell lymphoma

Interventions

Product Name: Cyclophosphamide Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Cyclophosphamide Concentration unit: mg milligram(s) Concentration type: equal Concentration

Sponsors

G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: valutare, in pazienti con linfoma mantellare in prima diagnosi, l'efficacia della combinazione R-HyperCVAD in termini di risposta completa ;Secondary Objective: valutare la sopravvivenza libera da malattia;valutare la sopravvivenza globale dei pazienti trattati;valutare la percentuale di risposte molecolari;valutare la tossicita' del programma di trattamento. ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026